RecruitingNCT06715007

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases


Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

300 participants

Start Date

Dec 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).


Eligibility

Min Age: 30 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aspirin, a drug called Cilostazol + Isosorbide Mononitrate, and others for people with small vessel cerebrovascular disease, stroke, ischemic, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClopidogrel

Patients will take Clopidogrel

DRUGAspirin

Patients will take Rivaroxaban

DRUGCilostazol + Isosorbide Mononitrate

Patients will take Cilostazol plus Isosorbide Mononitrate


Locations(1)

the First affiliated hospital of Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06715007


Related Trials